Olivier Garraud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4360048/publications.pdf

Version: 2024-02-01

289 papers

7,751 citations

45 h-index 72 g-index

361 all docs

361 does citations

361 times ranked

7805 citing authors

#	Article	IF	CITATIONS
1	Anemia in the very aged person: How are treatment options discussed and when is red blood cell component transfusion proposed?. Transfusion and Apheresis Science, 2022, , 103361.	0.5	O
2	Platelets as Key Factors in Inflammation: Focus on CD40L/CD40. Frontiers in Immunology, 2022, 13, 825892.	2.2	48
3	A tribute to an inspirational colleague in transfusion medicine, Professor Anneke Brand. Transfusion Clinique Et Biologique, 2022, 29, 1-2.	0.2	O
4	The best use of the French donors' gift–ÂContinuing an ethical tradition. Transfusion Clinique Et Biologique, 2022, 29, 189-190.	0.2	1
5	Platelet therapy and regenerative medicine: A need for clarification and controlled trials, and a desirable intervention for blood establishments. Transfusion and Apheresis Science, 2022, , 103463.	0.5	0
6	Review of indications for immunoglobulin (IG) use: Narrowing the gap between supply and demand. Transfusion Clinique Et Biologique, 2021, 28, 96-122.	0.2	26
7	Is plasma donation ethics abused?. Transfusion Clinique Et Biologique, 2021, 28, 1-2.	0.2	5
8	A look-back at convalescent plasma to treat COVID-19. Transfusion and Apheresis Science, 2021, 60, 103063.	0.5	11
9	Preventing transfusionâ€ŧransmitted malaria in France. Vox Sanguinis, 2021, 116, 943-945.	0.7	6
10	Effects and Side Effects of Platelet Transfusion. Hamostaseologie, 2021, 41, 128-135.	0.9	13
11	What has changed after the COVID-19 pandemic in the publication process? A look-back to "Transfusion clinique et biologique― Transfusion Clinique Et Biologique, 2021, 28, 129-131.	0.2	O
12	Convalescent plasma to treat COVID-19: Following the Argentinian lead. Transfusion and Apheresis Science, 2021, 60, 103161.	0.5	1
13	International collaboration for blood safety: The French—African experience. Transfusion Clinique Et Biologique, 2021, 28, 154-157.	0.2	3
14	Platelet Innate Immune Receptors and TLRs: A Double-Edged Sword. International Journal of Molecular Sciences, 2021, 22, 7894.	1.8	38
15	Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps. Transfusion Clinique Et Biologique, 2021, 28, 225-227.	0.2	О
16	Post-donation information management. Transfusion Clinique Et Biologique, 2021, 28, 407-413.	0.2	6
17	Transfusion at the border of the "intention-to-treatâ€; in the very aged person and in palliative care: A debate. Transfusion Clinique Et Biologique, 2021, 28, 367-369.	0.2	6
18	Residents' knowledge in transfusion medicine and educational programs: A pilot study. Transfusion Clinique Et Biologique, 2020, 27, 18-24.	0.2	10

#	Article	IF	CITATIONS
19	How to manage transfusion systems in developing countries: The Experience of Eastern and Southern Mediterranean countries. Transfusion Medicine, 2020, 30, 7-15.	0.5	8
20	Medical student education in transfusion medicine, part II: Moving forward to building up a "Know How" education program in transfusion medicine for under-graduate medical students. Transfusion and Apheresis Science, 2020, 59, 102879.	0.5	3
21	Transfusion medicine: Overtime paradigm changes and emerging paradoxes. Transfusion Clinique Et Biologique, 2020, 27, 262-267.	0.2	2
22	How do I see the production of engineered blood cells available for transfusion?. Transfusion and Apheresis Science, 2020, 59, 102863.	0.5	5
23	COVID-19, transfusion, and publishing ethics. Transfusion Clinique Et Biologique, 2020, 27, 201-202.	0.2	3
24	Platelet-derived HMGB1: critical mediator of SARs related to transfusion. Annals of Translational Medicine, 2020, 8, 140-140.	0.7	13
25	Quality and safety measures in transfusion practice: The experience of eight southern/eastern Mediterranean countries. Vox Sanguinis, 2020, 115, 405-423.	0.7	6
26	The complexity of setting up clinical trials for the transfusion support of myelodysplastic syndromes: How to best serve the patients' interests?. Transfusion and Apheresis Science, 2020, 59, 102750.	0.5	3
27	Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?. Transfusion and Apheresis Science, 2020, 59, 102858.	0.5	11
28	Dysregulated pathways and differentially expressed proteins associated with adverse transfusion reactions in different types of platelet components. Journal of Proteomics, 2020, 218, 103717.	1.2	4
29	Platelet depletion limits the severity but does not prevent the occurrence of experimental transfusionâ€related acute lung injury. Transfusion, 2020, 60, 713-723.	0.8	13
30	Let us rejoice in the remarkable persistence of transfusion but remain alert to the risks in ambush. Transfusion Clinique Et Biologique, 2020, 27, 2.	0.2	2
31	Blood, perceptions, resource and ownership: When transfusion illustrates the complexity. Transfusion Clinique Et Biologique, 2020, 27, 91-95.	0.2	2
32	Information, consentement et transfusion sanguineÂ: compte rendu du 6e Séminaire d'éthique transfusionnelle de l'Institut national de la transfusion sanguine. Ethics, Medicine and Public Health, 2020, 12, 100423.	0.5	0
33	COVID-19: Is a paradigm change to be expected in health care and transfusion medicine?. Transfusion Clinique Et Biologique, 2020, 27, 59-60.	0.2	8
34	Difficulties in achieving a sustainable blood supply: report from the first national seminar on blood donation in Lebanon. Eastern Mediterranean Health Journal, 2020, 26, 736-743.	0.3	5
35	The plasma supply in France. Transfusion and Apheresis Science, 2019, 58, 358-362.	0.5	7
36	How to reposition the benefice–risk balance to safely transfuse patients in non-vital situations?. Transfusion Clinique Et Biologique, 2019, 26, 171-173.	0.2	6

#	Article	IF	Citations
37	Cytokines and related molecules, and adverse reactions related to platelet concentrate transfusions. Transfusion Clinique Et Biologique, 2019, 26, 144-146.	0.2	3
38	Data from differentially expressed proteins in platelet components associated with adverse transfusion reactions. Data in Brief, 2019, 25, 104013.	0.5	1
39	Platelet Inflammatory Response to Stress. Frontiers in Immunology, 2019, 10, 1478.	2.2	81
40	Still celebrate the World Blood Donor Day and shed light on blood donation needs and blood demand. Transfusion Clinique Et Biologique, 2019, 26, 197.	0.2	2
41	Les complications de la transfusion sanguine. Anesthésie & Réanimation, 2019, 5, 157-174.	0.1	1
42	Evidence of CD40L/CD40 pathway involvement in experimental transfusion-related acute lung injury. Scientific Reports, 2019, 9, 12536.	1.6	22
43	Immunological Features in the Process of Blood Platelet-Induced Alloimmunisation, with a Focus on Platelet Component Transfusion. Diseases (Basel, Switzerland), 2019, 7, 7.	1.0	10
44	Injectable immunoglobulins, immunodeficiency and off-label clinical trials, source plasma and ethical concerns and debates. Transfusion and Apheresis Science, 2019, 58, 529-530.	0.5	5
45	Biography: Prof. Dr. Olivier Garraud MD PhD. Transfusion and Apheresis Science, 2019, 58, 225.	0.5	0
46	Types of fresh plasma with focus on therapeutic plasma exchange. Transfusion and Apheresis Science, 2019, 58, 258-261.	0.5	3
47	Therapeutic plasma exchange, 2019 and beyond. Transfusion and Apheresis Science, 2019, 58, 226-227.	0.5	2
48	Plateletâ€derived extracellular vesicles convey mitochondrial DAMPs in platelet concentrates and their levels are associated with adverse reactions. Transfusion, 2019, 59, 2403-2414.	0.8	58
49	Blood donations mode: Assessment of the Lebanese model. Transfusion Clinique Et Biologique, 2019, 26, 341-345.	0.2	9
50	Inhibition of the CD40/CD40L complex protects mice against ALIâ€induced pancreas degradation. Transfusion, 2019, 59, 1090-1101.	0.8	4
51	Could platelet washing be used to reduce adverse reactions in patients receiving platelet component transfusions?. Annals of Blood, 2019, 4, 9-9.	0.4	1
52	Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpura. Transfusion and Apheresis Science, 2019, 58, 102665.	0.5	2
53	Platelet αâ€granules modulate the inflammatory response under systemic lipopolysaccharide injection in mice. Transfusion, 2019, 59, 32-38.	0.8	6
54	Differential protein expression of blood platelet components associated with adverse transfusion reactions. Journal of Proteomics, 2019, 194, 25-36.	1.2	11

#	Article	IF	CITATIONS
55	Soluble CD40L and CD62P levels differ in singleâ€donor apheresis platelet concentrates and buffy coat–derived pooled platelet concentrates. Transfusion, 2019, 59, 16-20.	0.8	10
56	Transfusion, history and ethics: Hundred years after WWI battlefield operations. Transfusion Clinique Et Biologique, 2019, 26, 1-2.	0.2	5
57	Platelet and TRALI: From blood component to organism. Transfusion Clinique Et Biologique, 2018, 25, 204-209.	0.2	11
58	Celebrating donors and the World Blood Donor Day 2018. Transfusion Clinique Et Biologique, 2018, 25, 101-102.	0.2	0
59	Transfusion-associated hazards: A revisit of their presentation. Transfusion Clinique Et Biologique, 2018, 25, 118-135.	0.2	31
60	Modeling the effect of platelet concentrate supernatants on endothelial cells: focus on endocan/ESMâ€1. Transfusion, 2018, 58, 439-445.	0.8	7
61	The way forward in transfusion medicine, from a French perspective…. Transfusion Clinique Et Biologique, 2018, 25, 1.	0.2	0
62	Platelet toll-like receptors are crucial sensors of infectious danger moieties. Platelets, 2018, 29, 533-540.	1.1	26
63	Theoretical and experimental ethics: advocacy for blood donors and beneficiaries of blood transfusions. Transfusion Medicine, 2018, 28, 261-262.	0.5	7
64	Rethinking transfusion medicine with a more holistic approach. Transfusion Clinique Et Biologique, 2018, 25, 81-82.	0.2	7
65	Amotosalen-inactivated plasma is as equally well tolerated as quarantine plasma in patients undergoing large volume therapeutic plasma exchange. Transfusion Clinique Et Biologique, 2018, 25, 73-77.	0.2	10
66	Linking transfusion and ecology is not so futile after all: A holistic reappraisal of transfusion and immunity. Transfusion Clinique Et Biologique, 2018, 25, 82-83.	0.2	0
67	Contrairement au tocilizumab, l'étanercept augmente légèrement l'agrégation plaquettaire expérimentale induite par la thrombine chez les sujets sains. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 514-516.	0.0	0
68	Molecular genetic diagnosis of Tunisian Glanzmann thrombasthenia patients reveals a common nonsense mutation in the ITGA2B gene that seems to be specific for the studied population. Blood Coagulation and Fibrinolysis, 2018, 29, 689-696.	0.5	1
69	Medical student education in transfusion medicine: Proposal from the "European and Mediterranean initiative in transfusion medicine― Transfusion and Apheresis Science, 2018, 57, 593-597.	0.5	12
70	Pathogen reduction or inactivation technologies for platelet components: Does decision making have to await further clinical trials?. Transfusion and Apheresis Science, 2018, 57, 797-798.	0.5	4
71	Platelet concentrate supernatants alter endothelial cell mRNA and protein expression patterns as a function of storage length. Transfusion, 2018, 58, 2635-2644.	0.8	11
72	Transfusion and refusal: trials and tribulations. International Journal of Clinical Transfusion Medicine, 2018, Volume 6, 15-20.	0.8	1

#	Article	IF	CITATIONS
73	Platelets: A more than a centenary old Odyssey and more to come. Transfusion Clinique Et Biologique, 2018, 25, 149-150.	0.2	0
74	Compte rendu du cinquiÓme séminaire d'éthique de l'Institut national de la transfusion sanguineÂ: quelles relations interpersonnelles sont-elles convoquées aux différentes étapes de la chaîne transfusionnelleÂ?. Ethics, Medicine and Public Health, 2018, 6, 139-145.	0.5	2
7 5	Pathogen inactivation/reduction technologies for platelet transfusion: Where do we stand?. Transfusion Clinique Et Biologique, 2018, 25, 165-171.	0.2	15
76	The Non-Hemostatic Aspects of Transfused Platelets. Frontiers in Medicine, 2018, 5, 42.	1.2	57
77	How Can Eastern/Southern Mediterranean Countries Resolve Quality and Safety Issues in Transfusion Medicine?. Frontiers in Medicine, 2018, 5, 45.	1.2	10
78	Blood and Blood Components: From Similarities to Differences. Frontiers in Medicine, 2018, 5, 84.	1.2	25
79	Plasma for direct therapeutic use, for today and tomorrow: A short critical overview. Transfusion Clinique Et Biologique, 2018, 25, 281-286.	0.2	10
80	How to mitigate the risk of inducing transfusion-associated adverse reactions. Transfusion Clinique Et Biologique, 2018, 25, 262-268.	0.2	18
81	Can a decentralized blood supply system reach 100% voluntary nonremunerated donation?. International Journal of Health Planning and Management, 2018, 33, e883-e891.	0.7	9
82	Assessment of soluble platelet CD40L and CD62P during the preparation process and the storage of apheresis platelet concentrates: Absence of factors related to donors and donations. Transfusion Clinique Et Biologique, 2018, 25, 192-196.	0.2	7
83	Leucocyte cytokines dominate platelet cytokines overtime in non-leucoreduced platelet components. Blood Transfusion, 2018, 16, 63-72.	0.3	6
84	About collection of blood and clinical use of blood components and ethical considerations—Thoughts from the Ethical Committee of the National Institute for Blood Transfusion, France. Hematologie, 2018, 24, 233-241.	0.0	0
85	Platelet components: is there need or room for quality control assays of storage lesions?. Blood Transfusion, 2018, 16, 1-3.	0.3	24
86	Apropos the 2016 world apheresis association and French society for hemapheresis meeting special issue. Transfusion and Apheresis Science, 2017, 56, 9.	0.5	0
87	Clinical trials in Transfusion Medicine and hemotherapy: Worth moving forward in evaluating †fresh' versus †old' blood cell components?. Transfusion and Apheresis Science, 2017, 56, 98-99.	0.5	9
88	A European survey on donor deferral for allergy: Rationale and initial results of a survey in 35Âcountries. Transfusion Clinique Et Biologique, 2017, 24, 34-35.	0.2	1
89	Determination of predictors of severity for recipient adverse reactions during platelet product transfusions. Transfusion Clinique Et Biologique, 2017, 24, 87-91.	0.2	3
90	Platelets and immunity: From physiology to pathology. Transfusion Clinique Et Biologique, 2017, 24, 83-86.	0.2	9

#	Article	IF	Citations
91	Can a decentralized blood system ensure self-sufficiency and blood safety? The Lebanese experience. Journal of Public Health Policy, 2017, 38, 359-365.	1.0	13
92	Appliquées à la transfusion, quelles sont les bases philosophiques de la bioéthique�. Ethics, Medicine and Public Health, 2017, 3, 216-220.	0.5	2
93	Transfusion clinique et biologique: A new era. Transfusion Clinique Et Biologique, 2017, 24, 1-2.	0.2	0
94	Hemolysis in six week-old autologous red blood cell components questioned: Worth addressing the issue of homologous components as well?. Transfusion and Apheresis Science, 2017, 56, 261-262.	0.5	3
95	Use of convalescent plasma in Ebola virus infection. Transfusion and Apheresis Science, 2017, 56, 31-34.	0.5	26
96	"Transfusion Clinique et Biologique―–Âwhat makes transfusion medicine and biology so special?. Transfusion Clinique Et Biologique, 2017, 24, 403.	0.2	2
97	Platelet soluble CD40-ligand level is associated with transfusion adverse reactions in a mixed threshold-and-hit model. Blood, 2017, 130, 1380-1383.	0.6	34
98	Younger blood from older donors: Admitting ignorance and seeking stronger data and clinical trials?. Transfusion and Apheresis Science, 2017, 56, 635-636.	0.5	2
99	Acetylsalicylic acid differentially limits the activation and expression of cell death markers in human platelets exposed to Staphylococcus aureus strains. Scientific Reports, 2017, 7, 5610.	1.6	11
100	Are all therapeutic plasma preparations the same: Is it worth assessing them in clinical trials?. Transfusion and Apheresis Science, 2017, 56, 920-923.	0.5	4
101	Wound healing: time to look for intelligent, â€~natural' immunological approaches?. BMC Immunology, 2017, 18, 23.	0.9	47
102	Unlike tocilizumab, etanercept slightly increases experimental thrombin-induced aggregation in healthy individuals. Joint Bone Spine, 2017, 84, 373-375.	0.8	3
103	Properties of donated red blood cell components from patients with hereditary hemochromatosis. Transfusion, 2017, 57, 166-177.	0.8	12
104	Platelets and coagulation during bacterial infections. Hematologie, 2017, 23, 236-242.	0.0	0
105	NF-κB Links TLR2 and PAR1 to Soluble Immunomodulator Factor Secretion in Human Platelets. Frontiers in Immunology, 2017, 8, 85.	2.2	21
106	Effect of â∈œoldâ∈•versus â∈œfreshâ∈•transfused red blood cells on patientsâ∈™ outcome: probably more complex than appears. Journal of Thoracic Disease, 2017, 9, E146-E148.	0.6	21
107	Duration of red blood cell storage and inflammatory marker generation. Blood Transfusion, 2017, 15, 145-152.	0.3	29
108	Transfusion and ecology: sense, nonsense, or missense?. Blood Transfusion, 2017, 15, 274-275.	0.3	5

#	Article	IF	Citations
109	Transfusion as an Inflammation Hit: Knowns and Unknowns. Frontiers in Immunology, 2016, 7, 534.	2.2	55
110	Biological diagnosis of von Willebrand disease: analytical characteristics of Innovance vWF:Ac assay kit on STA-R Evolution Expert series analyzer (Stago). Annales De Biologie Clinique, 2016, 74, 355-364.	0.2	0
111	Bee Venom Accelerates Wound Healing in Diabetic Mice by Suppressing Activating Transcription Factorâ€3 (ATFâ€3) and Inducible Nitric Oxide Synthase (iNOS)â€Mediated Oxidative Stress and Recruiting Bone Marrowâ€Derived Endothelial Progenitor Cells. Journal of Cellular Physiology, 2016, 231, 2159-2171.	2.0	60
112	How can nonâ€nucleated platelets be so smart?. Journal of Thrombosis and Haemostasis, 2016, 14, 794-796.	1.9	16
113	Platelets and their immune role in anti-infective immunity. Future Microbiology, 2016, 11, 167-170.	1.0	5
114	Red blood cell antigen alloimmunization: Mysteries still unsolved. EBioMedicine, 2016, 9, 5-6.	2.7	4
115	Do we need [more] clinical trials in Transfusion Medicine and Hemotherapy?. Transfusion and Apheresis Science, 2016, 55, 262-263.	0.5	1
116	Ethics and blood donation: A marriage of convenience. Presse Medicale, 2016, 45, e247-e252.	0.8	12
117	The infectious risks in blood transfusion as of today – A no black and white situation. Presse Medicale, 2016, 45, e303-e311.	0.8	19
118	Blood transfusion in 2016â€"Towards a "Nouvelle Vague―therapy?. Presse Medicale, 2016, 45, e243-e245.	0.8	3
119	Levels of human platelet-derived soluble CD40 ligand depend on haplotypes of CD40LG-CD40-ITGA2. Scientific Reports, 2016, 6, 24715.	1.6	20
120	Blood donation and/or donated blood acceptance: The different stakeholders' ethical considerations. Ethics, Medicine and Public Health, 2016, 2, 213-219.	0.5	4
121	Platelet components associated with adverse reactions: predictive value of mitochondrial DNA relative to biological response modifiers. Transfusion, 2016, 56, 497-504.	0.8	41
122	Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfusion Clinique Et Biologique, 2016, 23, 39-44.	0.2	111
123	Transfusion-related acute lung injury: transfusion, platelets and biological response modifiers. Expert Review of Hematology, 2016, 9, 497-508.	1.0	30
124	"The Trampâ€; a blood donation propagandist?. Transfusion Clinique Et Biologique, 2016, 23, 55-57.	0.2	0
125	Improving platelet transfusion safety: biomedical and technical considerations. Blood Transfusion, 2016, 14, 109-22.	0.3	44
126	A prospective, active haemovigilance study with combined cohort analysis of 19Â175 transfusions of platelet components prepared with amotosalenâ€" <scp>UVA</scp> photochemical treatment. Vox Sanguinis, 2015, 109, 343-352.	0.7	73

#	Article	IF	Citations
127	Independent evaluation of tolerance of therapeutic plasma inactivated by amotosalen†scp>HC ⟨ scp> â€" (scp>UVA ⟨ scp> (Intercept (sup>)â,,¢ (sup>) over a 5†year period of extensive delivery. Vox Sanguinis, 2015, 109, 414-416.	2 O.7	18
128	Proposition d'un modèle relationnel de l'intention de donner son sangÂ: les effets de l'empowerment psychologique et de l'engagement. Journal De Gestion Et D économie Médicales, 2015, Vol. 33, 23-44.	0.3	6
129	Editorial: Platelets as Immune Cells in Physiology and Immunopathology. Frontiers in Immunology, 2015, 6, 274.	2.2	9
130	Still puzzling questions in immunology (infection and immunity). BMC Immunology, 2015, 16, 22.	0.9	2
131	Platelets and Infections ââ,¬â€œ Complex Interactions with Bacteria. Frontiers in Immunology, 2015, 6, 82.	2.2	188
132	Topical Application of Propolis Enhances Cutaneous Wound Healing by Promoting TGF-Beta/Smad-Mediated Collagen Production in a Streptozotocin-Induced Type I Diabetic Mouse Model. Cellular Physiology and Biochemistry, 2015, 37, 940-954.	1.1	104
133	Bloodletting for nonâ€medical reasons: what about safety and quality?. Transfusion Medicine, 2015, 25, 424-425.	0.5	2
134	An overview of the role of microparticles/microvesicles in blood components: Are they clinically beneficial or harmful?. Transfusion and Apheresis Science, 2015, 53, 137-145.	0.5	98
135	Development of a highly resolutive method, using a double quadruplex tetra-primer-ARMS-PCR coupled with capillary electrophoresis to study CD40LG polymorphisms. Molecular and Cellular Probes, 2015, 29, 335-342.	0.9	5
136	Viable but Not Culturable Forms of Legionella pneumophila Generated After Heat Shock Treatment Are Infectious for Macrophage-Like and Alveolar Epithelial Cells After Resuscitation on Acanthamoeba polyphaga. Microbial Ecology, 2015, 69, 215-224.	1.4	45
137	Are polymorphisms of the immunoregulatory factor CD40LG implicated in acute transfusion reactions?. Scientific Reports, 2015, 4, 7239.	1.6	20
138	Monitoring of Legionella pneumophila viability after chlorine dioxide treatment using flow cytometry. Research in Microbiology, 2015, 166, 215-219.	1.0	22
139	Breaking the Mold: Transcription Factors in the Anucleate Platelet and Platelet-Derived Microparticles. Frontiers in Immunology, 2015, 6, 48.	2.2	58
140	Platelet Transfusion ââ,¬â€œ The New Immunology of an Old Therapy. Frontiers in Immunology, 2015, 6, 28.	2.2	82
141	Specific activation, signalling and secretion profiles of human platelets following PAR-1 and PAR-4 stimulation. Platelets, 2015, 26, 795-798.	1.1	9
142	The inflammatory role of platelets via their TLRs and Siglec receptors. Frontiers in Immunology, 2015, 6, 83.	2.2	159
143	LPS stimulation of purified human platelets is partly dependent on plasma soluble CD14 to secrete their main secreted product, soluble-CD40-Ligand. BMC Immunology, 2015, 16, 3.	0.9	39
144	Are Platelets Cells? And if Yes, are They Immune Cells?. Frontiers in Immunology, 2015, 6, 70.	2.2	102

#	Article	IF	Citations
145	The role of microparticles in inflammation and transfusion: A concise review. Transfusion and Apheresis Science, 2015, 53, 159-167.	0.5	7 2
146	Immunogenicity of infectious pathogens and vaccine antigens. BMC Immunology, 2015, 16, 31.	0.9	53
147	Amotosalenâ€ <scp>HC</scp> lâ€ <scp>UVA</scp> pathogen reduction does not alter poststorage metabolism of soluble <scp>CD</scp> 40 ligand, Ox40 ligand and interkeukinâ€27, the cytokines that generally associate with serious adverse events. Vox Sanguinis, 2015, 108, 205-207.	0.7	9
148	Human platelets and their capacity of binding viruses: meaning and challenges?. BMC Immunology, 2015, 16, 26.	0.9	62
149	Is transfusion-transmitted dengue fever a potential public health threat?. World Journal of Virology, 2015, 4, 113.	1.3	37
150	Transfusion safety from the viewpoint of a musical quintet. Blood Transfusion, 2015, 13, 687.	0.3	7
151	Microarray Analysis of Cell Cycle Gene Expression in Adult Human Corneal Endothelial Cells. PLoS ONE, 2014, 9, e94349.	1.1	14
152	A Computerized Prediction Model of Hazardous Inflammatory Platelet Transfusion Outcomes. PLoS ONE, 2014, 9, e97082.	1.1	39
153	Role of Siglec-7 in Apoptosis in Human Platelets. PLoS ONE, 2014, 9, e106239.	1.1	36
154	Emerging Evidence for Platelets as Immune and Inflammatory Effector Cells. Frontiers in Immunology, 2014, 5, 653.	2.2	55
155	World Apheresis Association letter to the WHO: The World Apheresis Association urges the development of preparedness plans to make specific plasma available when urgently needed. Transfusion and Apheresis Science, 2014, 51, 2-3.	0.5	4
156	Removal of biologic response modifiers associated with platelet transfusion reactions: strategies worth considering?. Transfusion, 2014, 54, 2583-2583.	0.8	8
157	From Donor to Recipient: Current Questions Relating to Humoral Alloimmunization. Antibodies, 2014, 3, 130-152.	1.2	5
158	The Signaling Role of CD40 Ligand in Platelet Biology and in Platelet Component Transfusion. International Journal of Molecular Sciences, 2014, 15, 22342-22364.	1.8	140
159	Non-leukodepleted red blood cell transfusion in sepsis patients: beyond oxygenation, is there a risk of inflammation?. Critical Care, 2014, 18, 690.	2.5	3
160	Very Early Endothelial Cell Loss After Simultaneous Corneal Autograft and Allograft. Cornea, 2014, 33, 201-206.	0.9	5
161	Comparison of Endothelial Cell Density of Organ Cultured Corneas With Cornea Donor Study. Cornea, 2014, 33, 597-603.	0.9	12
162	Paths to Understand and to Limit Inflammation in Transfusions. European Journal of Inflammation, 2014, 12, 191-195.	0.2	2

#	Article	IF	CITATIONS
163	Immuneâ€reactive soluble <scp>OX</scp> 40 ligand, soluble <scp>CD</scp> 40 ligand, and interleukinâ€27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions. Transfusion, 2014, 54, 613-625.	0.8	57
164	Non-invasive measurement of transparency, arcus senilis, and scleral rim diameter of corneas during eye banking. Cell and Tissue Banking, 2014, 15, 471-482.	0.5	9
165	Health care-associated hepatitis C virus infection. World Journal of Gastroenterology, 2014, 20, 17265.	1.4	39
166	Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood, 2014, 124, 2173-2183.	0.6	513
167	Blood and blood-associated symbols beyond medicine and transfusion: far more complex than first appears. Blood Transfusion, 2014, 12, 14-21.	0.3	18
168	Problématiques éthiques anciennes et nouvelles en transfusion sanguine. Hematologie, 2014, 20, 166-171.	0.0	0
169	Investigative <i>In Vitro</i> Study about Red Blood Cell Concentrate Processing and Storage. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 216-217.	2,5	9
170	The effects of red blood cell preparation method on in vitro markers of red blood cell aging and inflammatory response. Transfusion, 2013, 53, 3128-3138.	0.8	40
171	Modelling and simulation of blood collection systems: improvement of human resources allocation for better costâ€effectiveness and reduction of candidate donor abandonment. Vox Sanguinis, 2013, 104, 225-233.	0.7	33
172	Bench-to-bedside review: Platelets and active immune functions - new clues for immunopathology?. Critical Care, 2013, 17, 236.	2.5	66
173	Comparison of apheresis and 24h RT held red cell concentrates by measurement of storage lesion parameters and neutrophil activating factors during 42-day storage. Transfusion and Apheresis Science, 2013, 48, 169.	0.5	11
174	Highly Active Antiretroviral Therapy Alters Inflammation Linked to Platelet Cytokines in HIV-1-Infected Patients. Journal of Infectious Diseases, 2013, 208, 868-870.	1.9	31
175	A regional haemovigilance retrospective study of four types of therapeutic plasma in a ten-year survey period in France. Vox Sanguinis, 2013, 104, 337-341.	0.7	31
176	Education in transfusion medicine for medical students and doctors. Vox Sanguinis, 2013, 104, 250-272.	0.7	26
177	Platelet concentrates for transfusion: Preparation, principle and safety criteria for optimal tolerance and reduction of hazards. Hematologie, 2013, 19, 371-382.	0.0	2
178	Do manual and automated processes with distinct additive solutions affect whole blood-derived platelet components differently?. Blood Transfusion, 2013, 11, 152-3.	0.3	13
179	Are there still myths in -or associated with- transfusion?. Blood Transfusion, 2013, 11, 148-50.	0.3	11
180	Single nucleotidic polymorphism 844 A->G of FCAR is not associated with IgA nephropathy in Caucasians. Nephrology Dialysis Transplantation, 2012, 27, 656-660.	0.4	2

#	Article	IF	CITATIONS
181	Transfusion in elderly patient. Hematologie, 2012, 18, 212-220.	0.0	1
182	Thymoquinone ameliorates the immunological and histological changes induced by exposure to imidacloprid insecticide. Journal of Toxicological Sciences, 2012, 37, 1-11.	0.7	68
183	An algorithm based on one or two nasal samples is accurate to identify persistent nasal carriers of Staphylococcus aureus. Clinical Microbiology and Infection, 2012, 18, 551-557.	2.8	38
184	Treatment of diabetic mice with undenatured whey protein accelerates the wound healing process by enhancing the expression of MIP-1Î \pm , MIP-2, KC, CX3CL1 and TGF-Î 2 in wounded tissue. BMC Immunology, 2012, 13, 32.	0.9	70
185	Revisited Microanatomy of the Corneal Endothelial Periphery: New Evidence for Continuous Centripetal Migration of Endothelial Cells in Humans. Stem Cells, 2012, 30, 2523-2534.	1.4	124
186	Platelets and cytokines: How and why?. Transfusion Clinique Et Biologique, 2012, 19, 104-108.	0.2	35
187	Human platelets can discriminate between various bacterial LPS isoforms via TLR4 signaling and differential cytokine secretion. Clinical Immunology, 2012, 145, 189-200.	1.4	124
188	Quantification by Real-Time PCR Assay of Staphylococcus aureus Load: a Useful Tool for Rapidly Identifying Persistent Nasal Carriers. Journal of Clinical Microbiology, 2012, 50, 2063-2065.	1.8	12
189	Human breast carcinoma cells are induced to apoptosis by samsum ant venom through an IGF-1-dependant pathway, PI3K/AKT and ERK signaling. Cellular Immunology, 2012, 273, 10-16.	1.4	38
190	Modeling and simulation of blood collection systems. Health Care Management Science, 2012, 15, 63-78.	1.5	53
191	Infectious transfusion risks: myth or reality?. Blood Transfusion, 2012, 10, 547-9.	0.3	7
192	Pathogen sensing, subsequent signalling, and signalosome in human platelets. Thrombosis Research, 2011, 127, 283-286.	0.8	36
193	Blood transfusion: current debates. Hematologie, 2011, 17, 71-87.	0.0	0
194	<i>In vitro</i> assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood Systemâ,,¢). Vox Sanguinis, 2011, 100, 247-249.	0.7	29
195	Complexes between nuclear factor-κB p65 and signal transducer and activator of transcription 3 are key actors in inducing activation-induced cytidine deaminase expression and immunoglobulin A production in CD40L plus interleukin-10-treated human blood B cells. Clinical and Experimental Immunology, 2011, 166, 171-183.	1.1	13
196	Streptococcus sanguinisâ€induced cytokine release from platelets. Journal of Thrombosis and Haemostasis, 2011, 9, 2038-2049.	1.9	20
197	Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study. Infection, Genetics and Evolution, 2011, 11, 496-503.	1.0	14
198	Optimization of immunolocalization of cell cycle proteins in human corneal endothelial cells. Molecular Vision, 2011, 17, 3494-511.	1.1	22

#	Article	IF	CITATIONS
199	Tollâ€ike receptor 4 signal transduction in platelets: novel pathways. British Journal of Haematology, 2010, 151, 89-92.	1.2	43
200	Pathogen inactivation of platelet concentrates. Vox Sanguinis, 2010, 99, 85-95.	0.7	23
201	Schistosomiasis Coinfection in Children Influences Acquired Immune Response against Plasmodium falciparum Malaria Antigens. PLoS ONE, 2010, 5, e12764.	1.1	59
202	Transfusion sanguine: débats d'actualité 2010. Hematologie, 2010, 16, 29-46.	0.0	0
203	Platelet Toll-Like Receptor Expression: The Link Between & amp; #x201C; Danger & amp; #x201D; Ligands and Inflammation. Inflammation and Allergy: Drug Targets, 2010, 9, 322-333.	1.8	55
204	Ex vivo Gene Electrotransfer to the Endothelium of Organ Cultured Human Corneas. Ophthalmic Research, 2010, 43, 43-55.	1.0	20
205	La symbolique duÂsang etÂlaÂtransfusion sanguine chezÂlesÂTémoins deÂJéhovah. Hematologie, 2009, 15, 460-472.	0.0	2
206	Extremely low doses of lepirudin in a patient with heparinâ€induced thrombocytopenia, high bleeding risk and renal insufficiency. British Journal of Haematology, 2009, 146, 456-457.	1.2	6
207	A near fatal septic transfusion reaction due to <i>StreptococcusÂdysgalactiae</i> equisimilis calls for novel safety measures. Vox Sanguinis, 2009, 96, 271-271.	0.7	7
208	Donor platelets stored for at least 3 days can elicit activation marker expression by the recipient's blood mononuclear cells: an in vitro <i>s</i> tudy. Transfusion, 2009, 49, 91-98.	0.8	36
209	Thrombin generation and heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2009, 7, 1474-1481.	1.9	40
210	Altered release of regulated upon activation, normal T-cell expressed and secreted protein from human, normal platelets: contribution of distinct HIV-1MN gp41 peptides. Aids, 2009, 23, 2057-2059.	1.0	20
211	L'information auxÂpatients enÂtransfusion sanguine. Hematologie, 2009, 15, 344-353.	0.0	6
212	Tissue-Specific B-Cell Dysfunction and Generalized Memory B-Cell Loss during Acute SIV Infection. PLoS ONE, 2009, 4, e5966.	1.1	65
213	Successful primate immunization with peptides conjugated to purified protein derivative or mycobacterial heat shock proteins in the absence of adjuvants. Clinical and Experimental Immunology, 2008, 93, 382-386.	1.1	68
214	Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment. Transfusion, 2008, 48, 809-813.	0.8	49
215	An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sanguinis, 2008, 94, 315-323.	0.7	105
216	Overview of revised measures to prevent malaria transmission by blood transfusion in France. Vox Sanguinis, 2008, 95, 226-231.	0.7	43

#	Article	IF	CITATIONS
217	Tollâ€like receptor 4 ligand can differentially modulate the release of cytokines by human platelets. British Journal of Haematology, 2008, 141, 84-91.	1.2	127
218	Identification of two subpopulations of purified human blood B cells, CD27 ^{â°'} â€fCD23 ⁺ and CD27 ^{high} â€fCD80 ⁺ , that strongly express cell surface Tollâ€ike receptor 9 and secrete high levels of interleukinâ€6. Immunology, 2008, 125, 430-437.	2.0	33
219	Direct contact of platelets and their released products exert different effects on human dendritic cell maturation. BMC Immunology, 2008, 9, 54.	0.9	63
220	Platelet components associated with acute transfusion reactions: the role of platelet-derived soluble CD40 ligand. Blood, 2008, 112, 4779-4780.	0.6	54
221	Reproducibility of Endothelial Assessment during Corneal Organ Culture: Comparison of a Computer-Assisted Analyzer with Manual Methods. , 2007, 48, 2062.		31
222	Platelets as Potential Immunomodulators: Is There a Role for Platelet Toll-Like Receptors?. Current Immunology Reviews, 2007, 3, 109-115.	1.2	12
223	Measures to prevent transfusion-associated protozoal infections in non-endemic countries. Travel Medicine and Infectious Disease, 2007, 5, 110-112.	1.5	24
224	Comparison of Two Semiautomated Methods for Evaluating Endothelial Cells of Eye Bank Corneas. , 2007, 48, 3077.		23
225	Human platelets can activate peripheral blood B cells and increase production of immunoglobulins. Experimental Hematology, 2007, 35, 1376-1387.	0.2	97
226	Lipopolysaccharide induces sCD40L release through human platelets TLR4, but not TLR2 and TLR9. Intensive Care Medicine, 2007, 33, 382-384.	3.9	49
227	An Active Hemovigilance Program Characterizing the Safety Profile of 7,437 Platelet Transfusions Prepared with Photochemical Treatment (INTERCEPTâ,,¢) Blood, 2007, 110, 2894-2894.	0.6	1
228	Mechanisms ofÂtransfusion-linked parasite infection. Transfusion Clinique Et Biologique, 2006, 13, 290-297.	0.2	21
229	Experimental Study of the Survival of Metastatic Cancer Cells in Corneal Organ Culture. , 2006, 47, 1339.		4
230	Transfusion-transmitted parasitic diseases or transfusion-transmitted parasites? Not just a matter of semantics. Vox Sanguinis, 2006, 91, 349-349.	0.7	3
231	Release of potential immunomodulatory factors during platelet storage. Transfusion, 2006, 46, 1184-1189.	0.8	135
232	Release of Immune Modulation Factors from Platelet Concentrates during Storage after Photochemical Pathogen Inactivation Blood, 2006, 108, 941-941.	0.6	1
233	Cytokines in Platelet Components Associated with Acute Transfusion Reactions: The Role of sCD40L Blood, 2006, 108, 952-952.	0.6	1
234	Efficacy comparison between anti-malarial drugs in Africans presenting with mild malaria in the Central Republic of Africa: a preliminary study. Parasite, 2005, 12, 73-77.	0.8	3

#	Article	IF	CITATIONS
235	Differential Downstream Effects of Cd40 Ligation Mediated by Membrane or Soluble CD40L and Agonistic Ab: A Study on Purified Human B Cells. International Journal of Immunopathology and Pharmacology, 2005, 18, 65-74.	1.0	23
236	Differential antibody responses to Plasmodium falciparum glycosylphosphatidylinositol anchors in patients with cerebral and mild malaria. Microbes and Infection, 2005, 7, 682-687.	1.0	35
237	Evidence of Tollâ€like receptor molecules on human platelets. Immunology and Cell Biology, 2005, 83, 196-198.	1.0	296
238	Human antibodies to the polymorphic block 2 domain of the Plasmodium falciparum merozoite surface protein 1 (MSPâ€1) exhibit a highly skewed, peptideâ€specific light chain distribution. Immunology and Cell Biology, 2005, 83, 392-395.	1.0	3
239	Human platelets exhibit infectious-pathogen–binding ligands and participate to inflammation (and) Tj ETQq1 1	0,7,84314	rgBT /Over
240	Flow cytometry identification and characterization of mononuclear cell subsets in the neotropical primate Saimiri sciureus (squirrel monkey). Journal of Immunological Methods, 2005, 297, 61-71.	0.6	7
241	Transfusion Related Acute Lung Injury (TRALI) Caused by Red Blood Cell Transfusion Involving Residual Plasma Anti-HLA Antibodies: A report on two Cases and General Considerations. Clinical and Developmental Immunology, 2005, 12, 243-248.	3.3	15
242	HIV Type 1 Glycoprotein 120 Inhibits Human B Cell Chemotaxis to CXC Chemokine Ligand (CXCL) 12, CC Chemokine Ligand (CCL)20, and CCL21. Journal of Immunology, 2005, 175, 302-310.	0.4	40
243	Efficiency of blood culture bottles for the fungal sterility testing of corneal organ culture media. British Journal of Ophthalmology, 2005, 89, 586-590.	2.1	33
244	Relationship of Binding of Immunoglobulin G to Plasmodium falciparum-Infected Erythrocytes with Parasite Endemicity and Antibody Responses to Conserved Antigen in Immune Individuals. Vaccine Journal, 2004, $11,6-11$.	2.6	9
245	Identification of Germinal Center B Cells in Blood from HIV-infected Drug-naive Individuals in Central Africa. Clinical and Developmental Immunology, 2004, 11, 23-27.	3.3	10
246	Specific Antibody Production by Blood B Cells is Retained in Late Stage Drug-na \tilde{A} -ve HIV-infected Africans. Clinical and Developmental Immunology, 2004, 11, 121-127.	3.3	4
247	Influence of blood prestorage conditions and white blood cell filtration on the bacterial load of blood deliberately inoculated with Gram-positive and Gram-negative pathogens. Vox Sanguinis, 2004, 87, 241-249.	0.7	17
248	Isotype profiles of anti-gp160 antibodies from HIV-infected patients in plasma and culture supernatants. Immunology Letters, 2004, 93, 57-62.	1.1	4
249	Urgent Need for Normalization of Corneal Graft Quality Controls in French Eye Banks. Transplantation, 2004, 78, 1299-1302.	0.5	24
250	Class and subclass selection in parasite-specific antibody responses. Trends in Parasitology, 2003, 19, 300-304.	1.5	73
251	Technique for obtaining highly enriched, quiescent immature Langerhans cells suitable for ex vivo assays. Immunology Letters, 2003, 86, 7-14.	1.1	13
252	A flow cytometry technique to study nuclear factor-kappa B (NFκB) translocation during human B cell activation. Immunology Letters, 2003, 90, 49-52.	1.1	16

#	Article	IF	CITATIONS
253	Differential production in vitro of antigen specific IgG1, IgG3 and IgA: a study in Schistosoma haematobium infected individuals. Parasite Immunology, 2003, 25, 39-44.	0.7	11
254	HIV-gp160 modulates differentially the production in vitro of IgG, IgA and cytokines by blood and tonsil B lymphocytes from HIV-negative individuals. Clinical and Experimental Immunology, 2003, 132, 304-308.	1.1	10
255	Malaria-specific antibody subclasses in immune individuals: a key source of information for vaccine design. Trends in Immunology, 2003, 24, 30-35.	2.9	58
256	Distinct Surrogate Markers for Protection againstPlasmodium falciparumInfection and Clinical Malaria Identified in a Senegalese Community after Radical Drug Cure. Journal of Infectious Diseases, 2003, 188, 1940-1950.	1.9	26
257	Regulation of Antigen-Specific Immunoglobulin G Subclasses in Response to Conserved and Polymorphic Plasmodium falciparum Antigens in an In Vitro Model. Infection and Immunity, 2002, 70, 2820-2827.	1.0	38
258	Evaluation of anti-Plasmodium falciparum antibodies in Senegalese adults using different types of crude extracts from various strains of parasite. Microbes and Infection, 2002, 4, 31-35.	1.0	31
259	Short report: differential evolution of immunoglobulin $G1/G3$ antibody responses to Plasmodium falciparum MSP1(19) over time in malaria-immune adult Senegalese patients American Journal of Tropical Medicine and Hygiene, 2002, 66, 137-139.	0.6	15
260	In vitro production of immunoglobulins of various classes and subclasses by cord blood B cells in African neonates: modeling and assessment of determination. Immunology Letters, 2001, 77, 119-124.	1.1	8
261	Gender-dependent specific immune response during chronic human Schistosomiasis haematobia. Clinical and Experimental Immunology, 2001, 124, 62-68.	1.1	57
262	Experimental IgG Antibody Production In vitro by Peripheral Blood and Tonsil Surface \hat{l}^3 + B Lymphocytes from Plasmodium falciparum -Immune West Africans. Scandinavian Journal of Immunology, 2001, 54, 606-612.	1.3	9
263	Short report: IgG1/IgG3 antibody responses to various analogs of recombinant ypfmsp119-a study in immune adults living in areas of Plasmodium falciparum transmission American Journal of Tropical Medicine and Hygiene, 2001, 64, 204-206.	0.6	15
264	Hyperexpression of ICAM-1 and CD36 in placentas infected with Plasmodium falciparum: a possible role of these molecules in sequestration of infected red blood cells in placentas. Histopathology, 2000, 36, 62-68.	1.6	16
265	Immunogenicity and Efficacy in Aotus Monkeys of Four Recombinant Plasmodium falciparum Vaccines in Multiple Adjuvant Formulations Based on the 19-Kilodalton C Terminus of Merozoite Surface Protein 1. Infection and Immunity, 2000, 68, 2215-2223.	1.0	89
266	Seasonal fluctuation of antibody levels to Plasmodium falciparum parasitized red blood cell-associated antigens in two Senegalese villages with different transmission conditions American Journal of Tropical Medicine and Hygiene, 2000, 62, 746-751.	0.6	16
267	Quantitative Computer Image Analysis of Chondroitin Sulfate A Expression in Placentas Infected withPlasmodium Falciparum. Journal of Histochemistry and Cytochemistry, 1999, 47, 751-756.	1.3	6
268	Immune responses to P. falciparum-MSP1 antigen: lack of correlation between antibody responses and the capacity of peripheral cellular immune effectors to respond to this antigen in vitro. Immunology Letters, 1999, 67, 217-221.	1.1	10
269	Different Plasmodium falciparum Recombinant MSP119Antigens Differ in Their Capacities to Stimulate In Vitro Peripheral Blood T Lymphocytes in Individuals from Various Endemic Areas. Scandinavian Journal of Immunology, 1999, 49, 431-440.	1.3	13
270	Secretion of parasiteâ€specific immunoglobulin G by purified blood B lymphocytes from immune individuals afterin vitrostimulation with recombinantPlasmodium falciparummerozoite surface proteinâ€119antigen. Immunology, 1999, 97, 204-210.	2.0	16

#	Article	IF	CITATIONS
271	Immune responses toPlasmodium falciparum–merozoite surface protein 1 (MSP1) antigen, II. Induction of parasiteâ€specific immunoglobulin G in unsensitized human B cells afterin vitroTâ€cell priming with MSP119. Immunology, 1999, 97, 497-505.	2.0	16
272	Regulation of immunoglobulin production in hyper-lgE (Job's) syndrome. Journal of Allergy and Clinical Immunology, 1999, 103, 333-340.	1.5	33
273	Flow cytometric analysis of IgG reactive to parasitized red blood cell membrane antigens in Plasmodium falciparum-immune individuals. Acta Tropica, 1999, 73, 175-181.	0.9	6
274	To the Editor: Analysis on reactivity of human lymphocyte and monocyteâ€specific antibodies with peripheral blood mononuclear cells from squirrel monkeys (⟨i⟩Saimiri sciureus⟨/i⟩). Journal of Medical Primatology, 1998, 27, 220-222.	0.3	2
275	Imbalanced distribution of IgM and IgG antibodies against Plasmodium falciparum antigens and merozoite surface protein-1 (MSP1) in pregnancy. Immunology Letters, 1998, 61, 197-199.	1.1	8
276	Plasmodium falciparum- and merozoite surface protein 1-specific antibody isotype balance in immune Senegalese adults. Infection and Immunity, 1997, 65, 4873-4876.	1.0	37
277	Induction of parasite antigen-specific antibody responses in unsensitized human B cells is dependent on the presence of cytokines after T cell priming. Journal of Immunology, 1997, 159, 4793-8.	0.4	9
278	The role of cytokines in human B-cell differentiation into immunoglobulin-secreting cells. Bulletin De L'Institut Pasteur, 1996, 94, 285-309.	0.7	25
279	Differential regulation of antigen-specific IgG4 and IgE antibodies in response to recombinant filarial proteins. International Immunology, 1996, 8, 1841-1848.	1.8	24
280	Induction of opsonizing antibodies after injection of recombinant Plasmodium falciparum vaccine candidate antigens in preimmune Saimiri sciureus monkeys. Infection and Immunity, 1995, 63, 554-562.	1.0	32
281	Identification of recombinant filarial proteins capable of inducing polyclonal and antigen-specific IgE and IgG4 antibodies. Journal of Immunology, 1995, 155, 1316-25.	0.4	61
282	Assays for adjuvanticity of new formulations and of carrier proteins for inducing antibody responses to selected immunogens in the squirrel monkey <i>Saimiri sciureus</i> . Immunology and Cell Biology, 1994, 72, 169-175.	1.0	4
283	Manipulating blood T cells and B cells from squirrel monkeys: some technical considerations. Journal of Immunological Methods, 1994, 173, 165-173.	0.6	14
284	Squirrel monkey (Saimiri sciureus) B lymphocytes: Secretion of IgG directed to Plasmodium falciparum antigens, by primed blood B lymphocytes restimulated in vitro with parasitized red blood cells. Research in Immunology, 1993, 144, 407-418.	0.9	7
285	FcÎ ³ R-expressing monocytes are necessary for PWM-induced proliferation of Saimiri sciureus peripheral blood mononuclear cells. Research in Immunology, 1993, 144, 129-139.	0.9	3
286	FLOW CYTOMETRIC DETECTION OF IN VITRO SECRETED ANTIBODIES AGAINST P. FALCIPARUM ANTIGENS THAT RECOGNIZE THE SURFACE OF THE INFECTED RED BLOOD CELLS OF SAIMIRI MONKEYS. Biology of the Cell, 1993, 79, 275-275.	0.7	1
287	Peripheral blood mononuclear cells in the squirrel monkey Saimiri sciureus II. — Exploration of the IL2/IL2R pathway of T-cell activation. Research in Immunology, 1991, 142, 773-787.	0.9	5
288	Functional characterization of the antibody-mediated protection against blood stages of Plasmodium falciparum in the monkey Saimiri sciureus. European Journal of Immunology, 1990, 20, 2317-2323.	1.6	58

#	Article	IF	CITATIONS
289	Peripheral blood mononuclear cells in the squirrel monkey Saimiri sciureus: Characterization and functional aspects of T lymphocytes. Research in Immunology, 1989, 140, 857-874.	0.9	15